Erasca, Inc.
ERAS$563M
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaSAN DIEGO103 employees
Drugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
ERAS News
Catalyst Timeline
0 upcoming, 1 past
No catalysts found.
Drug Pipeline
Naporafenib
Advanced or Metastatic NRAS-mutant Melanoma
Encorafenib
Metastatic Colorectal Cancer
ERAS-007
Advanced or Metastatic Solid Tumors
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Naporafenib | Phase 3 | Advanced or Metastatic NRAS-mutant Melanoma | - | - |
Encorafenib | Phase 2 | Metastatic Colorectal Cancer | - | - |
ERAS-007 | Phase 2 | Advanced or Metastatic Solid Tumors | - | - |
Advanced or Metastatic NRAS-mutant Melanoma
1 drug in this indication
Metastatic Colorectal Cancer
1 drug in this indication
Advanced or Metastatic Solid Tumors
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply